• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头孢氨苄:与肾功能和血液透析相关的吸收和排泄。

Cephalexin: absorption and excretion as related to renal function and hemodialysis.

机构信息

Infectious Disease Laboratory, Chicago Wesley Memorial Hospital and Infectious Diseases-Hypersensitivity and Renal Sections, Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611.

出版信息

Infect Immun. 1971 Apr;3(4):540-3. doi: 10.1128/iai.3.4.540-543.1971.

DOI:10.1128/iai.3.4.540-543.1971
PMID:16558013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC416192/
Abstract

Cephalexin is a new semisynthetic cephalosporin C derivative, which is well absorbed from the gastrointestinal tract and excreted in high concentration in the urine. Even in patients with impaired renal function, the concentrations of cephalexin present in the urine are adequate for the treatment of most urinary tract infections produced by Escherichia coli, Klebsiella, and Proteus mirabilis. In anephric patients, single doses of 250 or 500 mg of cephalexin resulted in high, prolonged serum concentrations. Peak levels were usually observed within 1 hr. However, in two of six anephric patients, peak levels were reached after 6 and 12 hr due to delayed absorption. Hemodialysis for 6 hr reduced the serum concentration of cephalexin by 58%.

摘要

头孢氨苄是一种新型半合成头孢菌素 C 衍生物,它从胃肠道吸收良好,并以高浓度排泄在尿液中。即使在肾功能受损的患者中,头孢氨苄在尿液中的浓度也足以治疗大多数由大肠杆菌、克雷伯菌和奇异变形杆菌引起的尿路感染。在无肾患者中,单次给予 250 或 500 毫克头孢氨苄可导致高浓度、长时间的血清浓度。峰浓度通常在 1 小时内观察到。然而,在 6 名无肾患者中,由于吸收延迟,有 2 名患者在 6 小时和 12 小时后达到了峰值水平。6 小时血液透析可使头孢氨苄的血清浓度降低 58%。

相似文献

1
Cephalexin: absorption and excretion as related to renal function and hemodialysis.头孢氨苄:与肾功能和血液透析相关的吸收和排泄。
Infect Immun. 1971 Apr;3(4):540-3. doi: 10.1128/iai.3.4.540-543.1971.
2
In vitro antimicrobial activity and human pharmacology of cephalexin, a new orally absorbed cephalosporin C antibiotic.新型口服吸收性头孢菌素C抗生素头孢氨苄的体外抗菌活性及人体药理学
Appl Microbiol. 1969 Mar;17(3):457-61. doi: 10.1128/am.17.3.457-461.1969.
3
Cephalexin and cephaloglycin activity in vitro and absorption and urinary excretion of single oral doses in normal young adults.头孢氨苄和头孢甘氨酸在体外的活性以及正常年轻成年人单次口服剂量后的吸收和尿排泄情况。
Appl Microbiol. 1968 Nov;16(11):1684-94. doi: 10.1128/am.16.11.1684-1694.1968.
4
Evaluation of cefaclor.头孢克洛的评估。
Am J Hosp Pharm. 1981 Jan;38(1):54-8.
5
Laboratory evaluation of FR10612, a new oral cephalosporin derivative.新型口服头孢菌素衍生物FR10612的实验室评估
J Antibiot (Tokyo). 1976 Apr;29(4):444-59. doi: 10.7164/antibiotics.29.444.
6
Cephalexin in the therapy of infections of the urinary tract.头孢氨苄用于治疗泌尿系统感染。
Postgrad Med J. 1983;59 Suppl 5:40-2.
7
In vitro antimicrobial activity and human pharmacology of cephaloglycin.头孢甘氨酸的体外抗菌活性及人体药理学
Appl Microbiol. 1968 Jul;16(7):1006-10. doi: 10.1128/am.16.7.1006-1010.1968.
8
Comparison of pharmacological and antimicrobial properties of cefadroxil and cephalexin.头孢羟氨苄与头孢氨苄的药理及抗菌特性比较。
Antimicrob Agents Chemother. 1977 Jul;12(1):93-7. doi: 10.1128/AAC.12.1.93.
9
Evaluation of antibacterial activities of cephalosporin antibiotics: cefazolin, cephaloridine, cephalothin, and cephalexin.头孢菌素类抗生素的抗菌活性评估:头孢唑林、头孢噻啶、头孢噻吩和头孢氨苄。
Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi. 1975 Mar;8(1):1-11.
10
Cephalexin: human studies of absorption and excretion of a new cephalosporin antibiotic.头孢氨苄:一种新型头孢菌素抗生素吸收与排泄的人体研究
Br J Pharmacol. 1969 Nov;37(3):738-47. doi: 10.1111/j.1476-5381.1969.tb08513.x.

引用本文的文献

1
Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.接受血液透析患者的药物治疗。临床药代动力学考量
Clin Pharmacokinet. 1984 Jan-Feb;9(1):42-66. doi: 10.2165/00003088-198409010-00003.
2
Cephalexin: a review of its antibacterial, pharmacological and therapeutic properties.头孢氨苄:对其抗菌、药理和治疗特性的综述。
Drugs. 1972;3(1):9-78. doi: 10.2165/00003495-197203010-00002.
3
Clinical pharmacokinetics of antibiotics in patients with impaired renal function.肾功能受损患者抗生素的临床药代动力学
Clin Pharmacokinet. 1992 Mar;22(3):169-210. doi: 10.2165/00003088-199222030-00002.
4
Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis.头孢克洛在终末期肾病患者及血液透析期间的药代动力学。
Antimicrob Agents Chemother. 1978 Sep;14(3):281-3. doi: 10.1128/AAC.14.3.281.

本文引用的文献

1
Laboratory and clinical experience with cephalexin.头孢氨苄的实验室及临床经验
Antimicrob Agents Chemother (Bethesda). 1968;8:361-5.
2
In vitro and in vivo evaluation of cephalexin.头孢氨苄的体外和体内评价。
Antimicrob Agents Chemother (Bethesda). 1968;8:296-301.
3
Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients.口服头孢氨苄和氨苄西林:尿毒症患者的抗菌活性、尿液中的回收率及血液中的持续时间
Ann Intern Med. 1970 Mar;72(3):349-56. doi: 10.7326/0003-4819-72-3-349.
4
Cephalexin therapy as related to renal function.与肾功能相关的头孢氨苄治疗
Am J Med Sci. 1970 Feb;259(2):133-42. doi: 10.1097/00000441-197002000-00007.
5
Clinical and in vitro evaluation of cephalexin. A new orally administered cephalosporin antibiotic.头孢氨苄的临床及体外评估。一种新型口服头孢菌素抗生素。
JAMA. 1969 Sep 1;209(9):1331-6.